Related Experiment Video
Updated: Jul 4, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.2K
Therapeutical Approach to Arterial Hypertension - Current State of the Art
Milica Radosavljevic1, Danijela Vučević2, Janko Samardžić1
1Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, 11000, Serbia.
Current Medicinal Chemistry
|February 2, 2024
Summary
Arterial hypertension (AH), a widespread cardiovascular disease affecting 1.28 billion globally, necessitates effective treatment to prevent severe complications. Ongoing research focuses on innovative pharmacotherapy and lifestyle interventions to manage this prevalent chronic condition.
Area of Science:
- Cardiology and Public Health
Background:
- Arterial hypertension (AH) is the most prevalent cardiovascular disease globally, impacting 1.28 billion individuals.
- It is a major contributor to cardiovascular diseases and premature mortality worldwide.
- Untreated elevated blood pressure can lead to life-threatening complications such as heart failure, stroke, and renal disorders.
Purpose of the Study:
- To highlight the critical importance of effective hypertension management.
- To emphasize the need for continuous innovation in antihypertensive pharmacotherapy.
- To underscore the role of diverse treatment approaches, including lifestyle modifications and novel medications.
Main Methods:
- Review of current understanding of hypertension prevalence and its complications.
- Analysis of established and evolving treatment strategies for arterial hypertension.
- Exploration of the impact of pharmacotherapy advancements on hypertension management.
Main Results:
- Hypertension affects a significant global population, underscoring the need for effective interventions.
- A combination of lifestyle changes and pharmacotherapy is crucial for managing blood pressure.
- The development of new antihypertensive medications is vital for addressing future challenges.
Conclusions:
- Effective management of arterial hypertension is essential to reduce global morbidity and mortality.
- A multifaceted approach, integrating lifestyle interventions with pharmacotherapy, is key to achieving normotensive blood pressure.
- Continued innovation in antihypertensive pharmacotherapy is critical for the future of cardiovascular health.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
734
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
734
01:23Antihypertensive Drugs: Vasodilators
525
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
525